Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 December;56(6) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 December;56(6):509-14

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 December;56(6):509-14

THERAPY AND DOSIMETRY IN NUCLEAR MEDICINE - AN UPDATE 

    SELECTED PRESENTATIONS

Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I

Pettinato C. 1, Monari F. 2, Nanni C. 3, Allegri V. 3, Marcatili S. 4, Civollani S. 1, Cima S. 2, Spezi E. 5, Mazzarotto R. 2, Fanti S. 3

1 Medical Physics Unit, Orsola-Malpighi University Hospital, Bologna, Italy;
2 Radiotherapy Unit, Orsola-Malpighi University Hospital, Bologna, Italy;
3 Nuclear Medicine Unit,Orsola-Malpighi University Hospital, Bologna, Italy;
4 PET Imaging Center, Cardiff University, School of Medicine, Cardiff, UK;
5 Department of Medical Physics, Velindre Cancer Centre, Cardiff, UK

AIM: The aim of this work was the evaluation of the usefulness of 124I PET/CT sequential scans to predict absorbed doses to metastatic thyroid cancer in patients undergoing 131I therapy.
METHODS: From July 2011 until April 2012 8 patients affected by metastatic thyroid cancer were enrolled. Each patient underwent 4 PET/CT scans at 4, 24, 48, 72 h after the administration of about 74 MBq of 124I. Blood samples and whole body exposure measurements were obtained to calculate blood and red marrow doses. Activity concentrations and lesion volumes obtained from PET/CT images were used to evaluate tumour doses with MIRD formalism and spheres model. The average administered 131I therapeutic activity was 6475 MBq (range: 3700-9250 MBq).
RESULTS: 124I PET/CT images showed, with a very good resolution, all 131I avid lesions detected by post therapy whole body scans. The average dose rates for blood, red marrow and lesions were respectively: 6.58E-02±1.64E-02 mGy/MBq, 5.73E-02±1.57E-02 mGy/MBq, 2.22E+01±1.62E+01 mGy/MBq. Three out of eight patients did not show any uptake of 124I in all PET/CT scans, despite high level of TSH and CT detectable lesions. Post-therapy 131I whole body scan confirmed the absence of focal iodine uptake.
CONCLUSION: Negative 124I PET/CT images probably could be used as predictive of real absence of iodine avidity, avoiding all toxicity from useless 131I therapy. A higher number of patients is necessary to validate these preliminary results and a project is ongoing to compare MIRD results to voxel dosimetry based on Monte Carlo simulation.

language: English


FULL TEXT  REPRINTS

top of page